Literature DB >> 7901766

Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway.

D Watling1, D Guschin, M Müller, O Silvennoinen, B A Witthuhn, F W Quelle, N C Rogers, C Schindler, G R Stark, J N Ihle.   

Abstract

Interferons (IFNs) alpha/beta (type I) and gamma (type II) bind to distinct cell surface receptors, inducing transcription of overlapping sets of genes by intracellular pathways that have recently attracted much attention. Previous studies using cell lines selected for their inability to respond to IFN-alpha (ref. 4) have shown that the protein kinase Tyk2 plays a central role in the IFN alpha/beta response. Here we report the isolation of the cell line gamma 1A, selected for its inability to express IFN-gamma-inducible cell-surface markers, that is deficient in all aspects of the IFN-gamma response tested, but responds normally to IFNs alpha and beta. The mutant cells can be complemented by the expression of another member of the JAK family of protein tyrosine kinases, JAK2 (refs 6-9). Unlike IFNs alpha and beta, IFN-gamma induces rapid tyrosine phosphorylation of JAK2 in wild-type cells, and JAK2 immunoprecipitates from these cells show tyrosine kinase activity. These responses are absent in gamma 1A cells. JAK2 is therefore required for the response to IFN-gamma but not to IFNs alpha and beta.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901766     DOI: 10.1038/366166a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  128 in total

1.  Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.

Authors:  P Saharinen; K Takaluoma; O Silvennoinen
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

2.  IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNgamma-responsive promoters in macrophages.

Authors:  C Contursi; I M Wang; L Gabriele; M Gadina; J O'Shea; H C Morse; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Distinct mechanisms of activation of Stat1 and Stat3 by platelet-derived growth factor receptor in a cell-free system.

Authors:  M L Vignais; M Gilman
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

4.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Authors:  Pipsa Saharinen; Mauno Vihinen; Olli Silvennoinen
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

5.  Replication of Toxoplasma gondii, but not Trypanosoma cruzi, is regulated in human fibroblasts activated with gamma interferon: requirement of a functional JAK/STAT pathway.

Authors:  I P Cerávolo; A C Chaves; C A Bonjardim; D Sibley; A J Romanha; R T Gazzinelli
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

6.  STAT1 from the cell membrane to the DNA.

Authors:  B F Lillemeier; M Köster; I M Kerr
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

Review 7.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

8.  Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2.

Authors:  Ivana De Domenico; Eric Lo; Diane M Ward; Jerry Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

9.  Involvement of the transcription factor PU.1/Spi-1 in myeloid cell-restricted expression of an interferon-inducible gene encoding the human high-affinity Fc gamma receptor.

Authors:  C Perez; E Coeffier; F Moreau-Gachelin; J Wietzerbin; P D Benech
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

10.  Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.

Authors:  H T Lu; J L Riley; G T Babcock; M Huston; G R Stark; J M Boss; R M Ransohoff
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.